Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 10,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.76, for a total value of $447,600.00. Following the completion of the sale, the insider now owns 95,034 shares of the company’s stock, valued at approximately $4,253,721.84. The trade was a 9.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.88, for a total value of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $49.87, for a total value of $498,700.00.

Akero Therapeutics Stock Down 0.3 %

Shares of NASDAQ:AKRO opened at $44.66 on Friday. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -11.91 and a beta of -0.19. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 12-month low of $17.86 and a 12-month high of $58.40. The business’s 50 day moving average is $43.53 and its 200 day moving average is $34.28.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AKRO. Wellington Management Group LLP boosted its position in Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares during the last quarter. Janus Henderson Group PLC boosted its position in Akero Therapeutics by 2.9% in the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock worth $203,053,000 after purchasing an additional 201,225 shares during the last quarter. RTW Investments LP boosted its position in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock worth $190,840,000 after purchasing an additional 940,388 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Akero Therapeutics by 13.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,321,972 shares of the company’s stock worth $120,238,000 after purchasing an additional 513,613 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Akero Therapeutics by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 3,704,411 shares of the company’s stock worth $103,057,000 after purchasing an additional 27,830 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. HC Wainwright lifted their target price on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. UBS Group boosted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, Citigroup boosted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics has a consensus rating of “Buy” and an average price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.